



vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

January 28, 2016

HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 28, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 2:00pm EST. The conference will be held at The Waldorf Astoria in New York City.

A live webcast of the presentation can be accessed on the [News & Events](#) section of the website. The webcast will be archived for 30 days following the presentation on the company website at www.vtvtherapeutics.com.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160128005877/en/>

Source: vTv Therapeutics Inc.

Investors

The Trout Group
Josh Barer, 646-378-2948
jbarer@troutgroup.com

or

Media

BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com